Safety and Efficacy of BMMNCin Patients With Mental Retardation

An Open Labeled Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Patients With Mental Retardation. It is Self Funded (Patients' Own Funding) Clinical Trial

Mental retardation is a condition diagnosed before age 18 that includes below-average general intellectual function, and a lack of the skills necessary for daily living. Mental retardation affects about 1 - 3% of the population. There are many causes of mental retardation, but find a specific reason in only 25% of cases.Bone marrow derived stem cells are used in this condition to prove its safety and efficacy .

Inclusion Criteria:

• Age limit: 5 -50
• Primary diagnosis of mental retardation (IQ < 70)
• willingness to undergo Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs) transplantation.
• To give an informed consent as well as sign the required Informed Consent Form (ICF)/video Consent for the study.
• willingness to regularly visit the hospital / clinic for follow up during the follow up period / on prior agreed time points as per the protocol.

Exclusion Criteria:

• Positive test results for HIV and AIDS complex ,HCV (hepatitis C virus ), HbsAg and Syphilis
• Advanced age that may produce deteriorating cognitive or motor functioning
• Multiple sensory or motor disabilities that will interfere with seeing the stimuli and responding to the computer
• Poor general health